Who should be tested for thrombophilia?

Current Opinion in Hematology

Volumn 13, Issue 5, 2006, Pages 337-343

  Simioni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Inherited thrombophilia; Laboratory screening; Pregnancy complications; Recurrent venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FOLIC ACID; HEPARIN; HORMONE; ORAL CONTRACEPTIVE AGENT; VITAMIN B GROUP;

ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT INHERITANCE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CANCER; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; FERTILE PERIOD; FETUS WASTAGE; HELLP SYNDROME; HETEROZYGOTE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; MASS SCREENING; PATIENT COUNSELING; PATIENT IDENTIFICATION; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIMIGRAVIDA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENT DISEASE; REVIEW; SKIN NECROSIS; SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33746706842     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000239705.25050.ff     Document Type: Review

References (59)

1. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004; 11:192-197.
2. Bauer KA. Role of thrombophilia in deciding on the duration of anticoagulation. Semin Thromb Hemost 2004; 30:633-637.
3. De Stefano V, Rossi E, Leone G. Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. Semin Vasc Med 2003; 3:47-60.
4. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17-25. The authors present a very interesting cost analysis of thrombophilia screening before hormone treatment.
5. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006; 10:1-110. This describes a decision analytical model developed to simulate clinical consequences of four thrombophilia screening scenarios. It provides a systematic review of screening for thrombophilia in high-risk situations.
6. ••].
7. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87:1095-1108.
8. Prandoni P. Venous thromboembolism risk and management in women with cancer and thrombophilia. Gend Med 2005; 2 (Suppl A):S28-S34.
9. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722.
10. Rosendaal FR Venous thrombosis: the role of genes, environment, and behavior. Hematology (Am Soc Hematol Educ Program) 2005; 1-12.
11. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155.
12. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95:3678-3682.
13. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696-701.
14. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3:79-84.
15. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18:242-248. The authors describe an upgrade on the risk of thrombosis associated with the antiphospholipid syndrome and on its management.
16. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295:1050-1057. This provides a comprehensive review on the management of antiphospholipid antibodies syndrome.
17. Ortel TL. Thrombosis and the antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program) 2005; 462-468.
18. Oger E, Lacut K, LE Gal G, et al. THE EDITH COLLABORATIVE STUDY GROUP. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006; 4:793-799.
19. McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 2005; 43:980-986.
20. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3:1646-1654.
21. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-1588. This paper is on the effect of lowering homocysteine in the risk of cardiovascular event after MI. No effect of treatment was observed.
22. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-1577. This is a paper on the effect of lowering homocysteine in vascular disease. No advantage of the treatment was observed.
23. Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. N Engl J Med 2006; 354:1629-1632.
24. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348:1435-1441.
25. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202.
26. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15-20.
27. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2:1526-1532.
28. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) J Thromb Haemost 2005; 3:459-464.
29. Simioni P, Castoldi E, Lunghi B, et al. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106:2363-2365.
30. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94:3702-3706.
31. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99:1938-1942.
32. Tormene D, Simioni P, Pagnan A, Prandoni P. The G20210A prothrombin gene mutation: is there room for screening families? J Thromb Haemost 2004; 2:1487-1488.
33. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
34. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106:4027-4033. This provides a practical overview on the management of VTE in cancer patients.
35. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005; 10:72-79.
36. Santamaria MG, Agnelli G, Taliani MR, et al. Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116:301-306.
37. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II Optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115:3-8.
38. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806.
39. Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa? J Thromb Haemost 2003; 1:16-18.
40. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis. Thromb Haemost 2000; 84:752-757.
41. Vink R, Kraaijenhagen RA, Levi M, Buller HR. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost 2003; 1:2523-2530.
42. Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology (Am Soc Hematol Educ Program) 2004; 424-438.
43. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166:729-736. This is an outstanding meta-analysis on the risk of recurrences of VTE in patients with common thrombophilic polymorphisms. Heterozygous carriers of FVL or PT G20210A present with an increased risk of VTE recurrences.
44. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:401S-428S.
45. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350:2558-2563.
46. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb 2002; 32:343-345.
47. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41:603-608.
48. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40:736-741.
49. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002; 100:2403-2405.
50. van Ommen CH, Heijboer H, van den Dool EJ, et al. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003; 1:2516-2522.
51. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1:915-921.
52. Nowak-Gottl U, Junker R, Kreuz W, et al., Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97:858-862.
53. Barnes C, Deveber G Prothrombotic abnormalities in childhood ischaemic stroke. Thromb Res 2005; Jul 20 [Epub ahead of print]
54. Robertson L, Wu O, Langhorne P, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132:171-196. The authors provide a systematic review on the risk of VTE and pregnancy complications associated with thrombophilia during pregnancy.
55. Lissalde-Lavigne G, Cochery-Nouvellon E, Mercier E, et al. The association between hereditary thrombophilias and pregnancy loss. Haematologica 2005; 90:1223-1230.
56. Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005; 3:1603-1610.
57. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005; 3:2178-2184. This was the first extensive study to demonstrate a role of common thrombophilic polymorphisms in predisposing to miscarriage in first intended pregnancy.
58. Brenner B, Bar J, Ellis M, et al. Live-Enox Investigators: Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 2005; 84:770-773. This provides a protocol for the prevention of pregnancy complications using enoxaparin in patients with recurrent fetal losses is discussed.
59. Brenner B, Hoffman R, Carp H, et al. LIVE-ENOX Investigators: Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3:227-229. This study compared two dose regimens for the prevention of pregnancy complications using enoxaparin in patients with recurrent fetal losses.